Troubled with Ads? Install Dainik Bhaskar app for news without ads
ParisOne hour ago
- Copy link
According to a study by France’s Pasteur Institute, people taking Pfizer’s doses were protected from the B.1.617 variant.
According to a study by the Pasteur Institute in France, the Pfizer vaccine is slightly less effective on corona patients, but it is still able to protect against the more infectious variants found in India. Olivier Schwartz, the institute’s director and co-author of the study, said that despite being slightly less effective, the Pfizer vaccine works against the B.1.617 variant. His study has been published on a website.
Sample of 28 healthcare workers for study
28 health care workers were sampled in the city of Orleans for the study. Of these, 16 were given two doses of the Pfizer vaccine. 12 was given a dose of the AstraZeneca vaccine. According to the study, a three-fold decrease in antibodies against the B.1.617 variant was observed among those who were given Pfizer’s doses, but they were safe even after that.
Schwartz said that patients who had been corona positive in the past year and were administered two Pfizer doses had enough antibodies to protect them from the variants found in India. However, it was 3 to 6 times lower than the antibody against the UK variant.
The variant found in India reached 53 countries
The SARS-CoV-2 virus (which is the cause of corona infection) has changed many forms since first meeting in China in late 2019. Where it was first met, it was recognized after his name. These include South Africa and the UK variant.
The variant found for the first time in India has a much wider spread than the earlier variant. According to a WHO report, it has been found in 53 countries so far. To prevent its spread, France and Germany have imposed stricter rules for those coming from affected countries, including the United Kingdom.